Specialty pharma companies, like Medexus Pharmaceuticals (MDP.T), have an advantage over tradition pharmaceutical drug developers as they provide pre-approved products and typically don’t need to go through the FDA approval process which can make or break traditional pharmaceutical ventures.

With its latest proposed portfolio addition, treosulfan, Medexus’ licensing partner Medac is providing some additional info to FDA to clear the drug for marketing and distribution in the US. The company already has a powerful portfolio on track to generate record revenues in the next quarter, but a brief delay in the treosulfan FDA process has needlessly spooked investors impacting the company’s share price.

In today’s episode, Chris speaks with Ken d’Entremont, CEO and director, of Medexus, to understand better why the FDA delay isn’t something that investors should be scared of and how the company’s current portfolio is strong and will provide tremendous revenue growth for Medexus over the next six months whatever the outcome of treosulfan’s approval process.

Enjoy!